Now showing items 1-7 of 7

    • Developing drugs for developing countries. 

      Grabowski, Henry G; Moe, Jeffrey L; Ridley, David Blaine (Health Aff (Millwood), 2006-03)
      Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments ...
    • Encouraging innovative treatment of neglected diseases through priority review vouchers 

      Grabowski, Henry G; Moe, Jeffrey L; Ridley, David Blaine (Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, 2009-09-01)
    • Entry and competition in generic biologics 

      Grabowski, Henry G; Ridley, David Blaine; Schulman, Kevin Alan (Managerial and Decision Economics, 2007-06-01)
      Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologies can and should be treated like pharmaceuticals with regard to generics. In ...
    • Priorities for the Priority Review Voucher. 

      Ridley, David Blaine (Am J Trop Med Hyg, 2017-01-11)
      The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease ...
    • Spending on postapproval drug safety. 

      Grabowski, Henry G; Kramer, JM; Ridley, David Blaine; Schulman, Kevin Alan; Tilson, HH (Health Aff (Millwood), 2006-03)
      Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding ...
    • Strategic interaction among governments in the provision of a global public good 

      Kyle, Margaret; Ridley, David Blaine; Zhang, S (Journal of Public Economics, 2017-12-01)
      © 2017 How do governments respond to other governments when providing a global public good? Using data from 2007 to 2014 on medical research funding for infectious and parasitic diseases, we examine how governments ...
    • The role of government reimbursement in drug shortages 

      Yurukoglu, A; Liebman, E; Ridley, David Blaine (American Economic Journal: Economic Policy, 2017-05-01)
      Beginning in the mid- 2000s, the incidence of drug shortages rose, especially for generic injectable drugs such as anesthetics and chemotherapy treatments. We examine whether reimbursement changes contributed to the shortages, ...